PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Orbis Biosciences, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Orbis Biosciences to Present at the 2012 Bio International Convention - Orbis Bioscience provides novel controlled release delivery systems to companies looking for an unprecedented level of precision in their microencapsulation and particle applications - OrbisBio.com
Orbis Biosciences to Present at the 2012 Bio International Convention

 

NewswireToday - /newswire/ - Kansas City, KS, United States, 2012/06/12 - Orbis Bioscience provides novel controlled release delivery systems to companies looking for an unprecedented level of precision in their microencapsulation and particle applications - OrbisBio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Orbis Biosciences, Inc. announced that they will be presenting at the 2012 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA. Orbis will present on Wednesday, June 20, from 2:15pm-2:30pm in the Patriots room.

“We are excited for the opportunity to present at this year’s BIO 2012 conference in Boston and share how our Precision Particle Fabrication technology provides novel controlled release delivery systems to companies looking for an unprecedented level of precision and cost-efficiency in their microencapsulation and particle applications,” explained Maria Flynn, CEO of Orbis Biosciences.

Orbis (orbisbio.com) will provide an in-depth discussion of the uses and applications of their Precision Particle Fabrication process. The presentation will highlight the technology’s single-step, solvent-free process of producing microencapsulated drug-matrix particles that offer, precise control of release rate (immediate and sustained), taste-masking, age-appropriate dosing, and dosage format variety. Orbis will also analyze and discuss the methodologies they use to create uniform particles and capsules with a narrow size distribution and exacting control over particle morphology.

About the Bio International Convention

The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. For registration, conference agenda and exhibitor information, visit 2012 BIO International Convention.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Orbis Biosciences, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Orbis Biosciences to Present at the 2012 Bio International Convention

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: David Dumbuld - OrbisBio.com 
913-945-7796 david[.]orbisbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Orbis Biosciences, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Orbis Biosciences, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Persistence Market Research (P) Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)